Preliminary data suggest promising anti-tumor activity of the combination of monalizumab and cetuximab in patients with platinum pretreated SCCHN
April 17, 20188 partial responses (PR) among 26 patients evaluable for efficacy – predefined number of responses needed to declare the trial result positive has been reached The combination was well tolerated,...New preclinical data further support ongoing programs and highlight next generation of immunotherapies
April 17, 2018Next generation of immunotherapies presented by Chief Scientific Officer Eric Vivier in a meet-the-expert session at AACR 2018 New preclinical data further support ongoing clinical trials with...Upcoming investor conferences
April 9, 2018Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor events: H.C. Wainwright Global Life Sciences Conference –...Partner MedImmune expands colorectal cancer patient cohort in ongoing Phase I trial evaluating monalizumab in combination with Imfinzi® (durvalumab)
March 23, 2018Additional expansion cohorts to explore the safety and efficacy of monalizumab in combination with durvalumab and standard of care in patients with 1 st - and 2 nd line, metastatic colorectal cancer...Innate Pharma to present broad and innovative portfolio in immuno-oncology at AACR 2018
March 15, 2018First clinical activity data of the combination of monalizumab and cetuximab New preclinical data further supporting the rationale of Innate’s first- or best-in-class antibodies Eric Vivier, Chief...Innate Pharma Hosts R&D Day Today in London
March 8, 2018Innate Pharma presents a clinical update on its broad and diverse development portfolio of first- or best-in-class antibodies in immuno-oncology Update on the development program with AstraZeneca on...
